Internal Medicine, Hematology & Oncology · San Antonio, TX
NPI
1275626970
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
5206 Research Dr
San Antonio, TX, 78240
Phone (210) 595-5300
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.9M
236,785 services
Medicare patients, 2024
809
Average age 74
Drug cost, 2024
$7.5M
1,565 prescriptions
Company payments, 2025
$708
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sridhar Beeram was code J9271 (injection, pembrolizumab, 1 mg), 32,600 times for 30 patients. In total Sridhar Beeram billed 236,785 services in 182 codes, and Medicare paid $4.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 32,600 | 30 | $44.80 | $1.5M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 15,560 | 11 | $2.30 | $36K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 13,260 | 17 | $0.27 | $3,584 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 11,550 | 38 | $0.11 | $1,296 |
| J9267 Injection, paclitaxel, 1 mg | Office | 10,251 | 17 | $0.08 | $813 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 9,700 | 12 | $0.06 | $548 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 7,690 | 20 | $36.99 | $284K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 5,446 | 53 | $0.10 | $567 |
| J0897 Injection, denosumab, 1 mg | Office | 4,320 | 15 | $18.03 | $78K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,116 | 69 | $0.09 | $188 |
| 36415 Venipuncture Blood Collection | Office | 1,600 | 445 | $8.65 | $14K |
| 80053 Clinical Chemistry | Office | 1,585 | 460 | $10.28 | $16K |
| 85025 Blood Count | Office | 1,544 | 450 | $7.56 | $12K |
| 83615 Clinical Chemistry | Office | 1,419 | 444 | $5.88 | $8,344 |
| 99214 Office E&M - Established | Office | 1,371 | 421 | $88.81 | $122K |
By year: 2022 $4.7M for 271,309 services; 2023 $4.7M for 229,065 services; 2024 $4.9M for 236,785 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,600 | 445 | $8.65 | $14K |
| 80053 Clinical Chemistry | 1,585 | 460 | $10.28 | $16K |
| 85025 Blood Count | 1,544 | 450 | $7.56 | $12K |
| 83615 Clinical Chemistry | 1,419 | 444 | $5.88 | $8,344 |
| 88185 Surgical Pathology Examination | 588 | 22 | $17.46 | $10K |
| 82784 Immunoassay | 381 | 51 | $9.11 | $3,472 |
| 82378 Clinical Chemistry | 279 | 70 | $18.29 | $5,103 |
| 82728 Clinical Chemistry | 241 | 104 | $13.24 | $3,192 |
| 83521 Immunoassay | 240 | 41 | $16.93 | $4,062 |
| 83540 Clinical Chemistry | 223 | 103 | $6.28 | $1,400 |
Medicare prescription drug claims, 2024
In 2024, the drug Sridhar Beeram prescribed most often to Medicare patients was Eliquis (Apixaban), with 317 prescriptions and refills. In total Sridhar Beeram wrote 1,565 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 317 | 379 | 54 | $217K |
| Anastrozole Generic | 103 | 265 | 32 | $1,309 |
| Xarelto Rivaroxaban | 73 | 137 | 19 | $75K |
| Jakafi Ruxolitinib Phosphate | 68 | 68 | Under 11 | $692K |
| Hydroxyurea Generic | 64 | 139 | 16 | $1,468 |
| Acyclovir Generic | 51 | 85 | 12 | $380 |
| Ondansetron Hcl Generic | 45 | 45 | 16 | $548 |
| Promacta Eltrombopag Olamine | 45 | 51 | Under 11 | $820K |
| Dexamethasone Generic | 44 | 45 | 13 | $625 |
| Cabometyx Cabozantinib S-Malate | 41 | 41 | Under 11 | $1.1M |
| Letrozole Generic | 40 | 97 | Under 11 | $707 |
| Brukinsa Zanubrutinib | 39 | 39 | Under 11 | $585K |
| Revlimid Lenalidomide | 37 | 37 | Under 11 | $575K |
| Lenalidomide Generic | 27 | 27 | Under 11 | $285K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 26 | 35 | 12 | $687 |
Brand drugs: 802 claims; generic drugs: 763 claims; opioid claims: 41.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sridhar Beeram $708 ($708 in general payments such as food, travel and fees) from 11 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $163.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $163 |
| Janssen Biotech, Inc. JNJ | 3 | $144 |
| Incyte Corporation INCY | 1 | $121 |
| Abbvie Inc. ABBV | 1 | $110 |
| Novocure Inc. NVCR | 1 | $55.56 |
| Pfizer Inc. PFE | 1 | $30.65 |
| Tempus AI, Inc TEM | 1 | $27.78 |
| Daiichi Sankyo Inc. 4568.T | 1 | $22.8 |
| Karyopharm Therapeutics Inc. KPTI | 1 | $17.25 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $15.29 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.